利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.025 秒)

    Pyridine-based thyroid receptor ligands
    2.
    发明授权
    Pyridine-based thyroid receptor ligands 失效
    基于吡啶的甲状腺受体配体

    公开(公告)号：US06747048B2

    公开(公告)日：2004-06-08

    申请号：US10431269

    申请日：2003-05-07

    申请人： Minsheng Zhang ,  Jon Hangeland ,  Yolanda Caringal ,  Todd Friends

    发明人： Minsheng Zhang ,  Jon Hangeland ,  Yolanda Caringal ,  Todd Friends

    IPC分类号： C07D21302

    CPC分类号： C07D213/69 ,  C07D213/68 ,  C07D213/70 ,  C07D213/73 ,  C07D213/74 ,  C07D213/75 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

    摘要： Novel pyridine-based thyroid receptor ligands are provided which have the general formula I wherein: X is oxygen (—O—), sulfur (—S—), sulfoxide (—S(O)—), sulfonyl (—SO2—), CR8R8 or NR8; Y is —NR8, oxygen (—O—), —CH2— or sulfur (—S—); Z is a bond or substituted or unsubstituted C1-4 alkyl; and wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

    摘要翻译： 提供了具有通式I的新型吡啶类甲状腺受体配体，其中X为氧（-O-），硫（-S-），亚砜（-S（O） - ），磺酰基（-SO 2 - ），CR 8 R 8 或NR8; Y是-NR8，氧（-O-），-CH2-或硫（-S-）; Z是取代或未取代的C1-4烷基; 并且其中取代基如本文所述。此外，提供了用于预防，抑制或治疗与代谢功能障碍相关的疾病或病症或依赖于T3调节基因的表达的方法，其中将上述化合物施用于 治疗有效量。

    Thyroid receptor ligands and method II
    3.
    发明授权
    Thyroid receptor ligands and method II 失效
    甲状腺受体配体及方法二

    公开(公告)号：US07288571B2

    公开(公告)日：2007-10-30

    申请号：US11189654

    申请日：2005-07-26

    申请人： Jon Hangeland ,  Minsheng Zhang ,  Yolanda Caringal ,  Denis Ryono ,  Yi-Lin Li ,  Johan Malm ,  Ye Liu ,  Neeraj Garg ,  Chris Litten ,  Ana Maria Garcia Collazo ,  Konrad Koehler

    发明人： Jon Hangeland ,  Minsheng Zhang ,  Yolanda Caringal ,  Denis Ryono ,  Yi-Lin Li ,  Johan Malm ,  Ye Liu ,  Neeraj Garg ,  Chris Litten ,  Ana Maria Garcia Collazo ,  Konrad Koehler

    IPC分类号： A61K31/18 ,  C07C311/50

    CPC分类号： C07D207/27 ,  C07C235/32 ,  C07C235/52 ,  C07C307/06 ,  C07C311/51 ,  C07C323/41 ,  C07C323/60 ,  C07D207/09 ,  C07D211/24 ,  C07D211/34 ,  C07D211/58 ,  C07D211/96 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D233/64 ,  C07D257/04 ,  C07D285/06 ,  C07D285/135 ,  C07D295/13 ,  C07D295/185 ,  C07D333/20

    摘要： New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereolsom thereof; or when n is equal to or greater than one, R4 may be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5—H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependant upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

    摘要翻译： 提供了具有通式（I）的新甲状腺受体配体，其中：n为0至4的整数; R 1是卤素，三氟甲基或1至6个碳的烷基或3至7个碳的环烷基; R 2和R 3相同或不同，为氢，卤素，1至4个碳的烷基或3至5个碳的环烷基，R 1， SUB 2和R 3不是氢; R 4是羧酸酰胺（CONR'R“）或酰基磺酰胺（CONHSO 2 R'）衍生物或其药学上可接受的盐及其所有立体异构体; 或当n等于或大于1时，R 4可以是可被取代或未取代的杂芳族部分，或胺（NR'R“）。 R 5是氢或酰基（如乙酰基或苯甲酰基）或能够生物转化以产生游离酚结构的其它基团（其中R 5 -H）。 此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关的疾病或依赖于T 3 N调节基因的表达的方法，其中如上所述的化合物以 治疗有效量。 与代谢功能障碍相关或依赖于T 3受体基因表达的这种疾病的实例包括肥胖症，高胆固醇血症，动脉粥样硬化，心律失常，抑郁症，骨质疏松症，甲状腺机能减退，甲状腺肿，甲状腺癌以及 青光眼，充血性心力衰竭和皮肤疾病。

    Thyroid receptor ligands and method II
    4.
    发明授权
    Thyroid receptor ligands and method II 失效
    甲状腺受体配体及方法二

    公开(公告)号：US06989402B1

    公开(公告)日：2006-01-24

    申请号：US09868889

    申请日：1999-12-23

    申请人： Jon Hangeland ,  Minsheng Zhang ,  Yolanda Caringal ,  Denis Ryono ,  Yi-Lin Li ,  Johan Malm ,  Ye Liu ,  Neeraj Garg ,  Chris Litten ,  Ana Maria Garcia Collazo ,  Konrad Koehler

    发明人： Jon Hangeland ,  Minsheng Zhang ,  Yolanda Caringal ,  Denis Ryono ,  Yi-Lin Li ,  Johan Malm ,  Ye Liu ,  Neeraj Garg ,  Chris Litten ,  Ana Maria Garcia Collazo ,  Konrad Koehler

    IPC分类号： A61K31/44 ,  A61K31/192 ,  A61K31/40 ,  A61K31/4174 ,  C07D211/56 ,  C07D213/72 ,  C07D229/38 ,  C07D265/30 ,  C07D241/04 ,  C07D207/14

    CPC分类号： C07D207/27 ,  C07C235/32 ,  C07C235/52 ,  C07C307/06 ,  C07C311/51 ,  C07C323/41 ,  C07C323/60 ,  C07D207/09 ,  C07D211/24 ,  C07D211/34 ,  C07D211/58 ,  C07D211/96 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D233/64 ,  C07D257/04 ,  C07D285/06 ,  C07D285/135 ,  C07D295/13 ,  C07D295/185 ,  C07D333/20

    摘要： New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

    摘要翻译： 提供了具有通式（I）的新甲状腺受体配体，其中：n为0至4的整数; R 1是卤素，三氟甲基或1至6个碳的烷基或3至7个碳的环烷基; R 2和R 3相同或不同，为氢，卤素，1至4个碳的烷基或3至5个碳的环烷基，R 1， SUB 2和R 3不是氢; R 4是羧酸酰胺（CONR'R“）或酰基磺酰胺（CONHSO 2 R'）衍生物或其药学上可接受的盐及其所有立体异构体; 或当n等于或大于1时，R 4可以是可被取代或未取代的杂芳族部分，或胺（NR'R“）。 R 5是氢或酰基（例如乙酰基或苯甲酰基）或能够生物转化以产生游离酚结构（其中R 5 = H）的其它基团。 此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关的疾病或依赖于T 3 N调节基因的表达的方法，其中如上所述的化合物以 治疗有效量。 与代谢功能障碍相关或依赖于T 3受体基因表达的这种疾病的实例包括肥胖症，高胆固醇血症，动脉粥样硬化，心律失常，抑郁症，骨质疏松症，甲状腺机能减退，甲状腺肿，甲状腺癌以及 青光眼，充血性心力衰竭和皮肤疾病。

    Aniline-derived ligands for the thyroid receptor
    8.
    发明申请
    Aniline-derived ligands for the thyroid receptor 有权
    苯胺衍生的甲状腺受体配体

    公开(公告)号：US20050032890A1

    公开(公告)日：2005-02-10

    申请号：US10930360

    申请日：2004-08-30

    申请人： Todd Friends ,  Denis Ryono ,  Minsheng Zhang

    发明人： Todd Friends ,  Denis Ryono ,  Minsheng Zhang

    IPC分类号： A61K45/00 ,  A61K31/155 ,  A61K31/167 ,  A61K31/192 ,  A61K31/22 ,  A61K31/351 ,  A61K31/40 ,  A61K31/404 ,  A61K31/425 ,  A61K31/4418 ,  A61K31/59 ,  A61K31/64 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P5/14 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P17/10 ,  A61P17/16 ,  A61P19/10 ,  A61P25/24 ,  A61P27/06 ,  A61P35/00 ,  A61P43/00 ,  C07C233/25 ,  C07C233/27 ,  C07C235/74 ,  C07C235/76 ,  A61K31/195 ,  A61K31/24

    CPC分类号： C07C233/27 ,  A61K31/167 ,  A61K45/06 ,  C07C233/25 ,  A61K2300/00

    摘要： New thyroid receptor ligands are provided which have the general formula in which: X is —O—, —S—, —CH2—, —CO—, or —NH—; Y is —(CH2)n— where n is an integer from 1 to 5, or cis- or trans-ethylene; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen; R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; R6 is carboxylic acid, or esters or prodrugs; R7 is hydrogen or an alkanoyl or an aroyl. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

    摘要翻译： 提供了新的甲状腺受体配体，其具有以下通式：其中：X是-O - ， - S - ， - CH 2 - ， - CO-或-NH-; Y是 - （CH 2）n - ，其中n是1至5的整数，或顺式或反式 - 亚乙基; R1是卤素，三氟甲基或1-6个碳的烷基或3-7个碳的环烷基; R2和R3相同或不同，为氢，卤素，1至4个碳的烷基或3至6个碳的环烷基，R2和R3中的至少一个不是氢; R4是氢或低级烷基; R5是氢或低级烷基; R6是羧酸，或酯或前药; R7是氢或烷酰基或芳酰基。 此外，提供了用于预防，抑制或治疗与代谢功能障碍相关的疾病或依赖于T3调节基因的表达的方法，其中以治疗有效量施用如上所述的化合物。 与代谢功能障碍相关或依赖于T3调节基因的表达的这些疾病的实例包括肥胖症，高胆固醇血症，动脉粥样硬化，心律失常，抑郁症，骨质疏松症，甲状腺功能减退，甲状腺癌以及青光眼，充血性心力衰竭和皮肤病 。